

Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment

Kyunghee Burkitt,^{1,3} Sang Y. Chun,^{1,3}
Duyen T. Dang,^{2,3} and Long H. Dang^{1,3}

Divisions of ¹Hematology/Oncology and ²Gastroenterology, Department of Internal Medicine, and ³University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan

Abstract

Sunitinib is an oral small-molecule multitargeted receptor tyrosine kinase inhibitor that has recently been shown to have clinical benefit as a single agent in renal cell cancer and gastrointestinal stromal tumors, leading to its Food and Drug Administration approval for treatment of these cancers. However, the benefit is short-lived; and for the majority of cancers, sunitinib single-agent clinical activity is low. Therefore, combination strategies with sunitinib are currently in clinical development. The hypoxia-inducible transcription factors, HIF-1 and HIF-2, induce gene programs important for cancer cell growth and angiogenesis. We hypothesized that inhibiting HIF-1 and HIF-2 would further improve tumor response to sunitinib therapy. To test this hypothesis, *HIF-1 α* and *HIF-2 α* genes were disrupted in colon cancer cells. We found that disruption of *HIF-1 α* , *HIF-2 α* , or both *HIF-1 α* and *HIF-2 α* genes led to improved tumor response to sunitinib. For xenografts in which both *HIF-1 α* and *HIF-2 α* genes were disrupted, there was prolonged complete remission with sunitinib treatment in 50% of mice. This enhanced response was mediated by two potential mechanisms. First, tumor angiogenesis and perfusion were almost completely inhibited by sunitinib when both *HIF-1 α* and *HIF-2 α* genes were disrupted. The enhanced inhibitory effect on tumor angiogenesis was mediated by the inhibition of multiple proangiogenic factors, including vascular endothelial growth factor and angiopoietin-like protein 4, and the induction of the antiangiogenic

factor, thrombospondin 1. Second, disruption of *HIF-1 α* , *HIF-2 α* , or both *HIF-1 α* and *HIF-2 α* genes directly inhibited tumor cell proliferation. These preclinical findings have clinical implications and suggest novel clinical trials. [Mol Cancer Ther 2009;8(5):1148–56]

Introduction

Sunitinib is a multitargeted receptor tyrosine kinase inhibitor that exhibits inhibitory activity against multiple targets including c-KIT, vascular endothelial growth factor receptors (VEGFR; VEGFR1, VEGFR2, and VEGFR3), platelet-derived growth factor receptors (α and β), FLT3, CSF-1R, and RET (1–7). Inhibition of these receptor tyrosine kinases blocks transduction of signals important for tumor growth, survival, and angiogenesis. Phase II and III clinical trials with sunitinib have shown clinical benefit, with significantly improved time to progression in patients with imatinib-resistant gastrointestinal stromal tumors and advanced renal cell cancer (6–9). However, this clinical response to sunitinib is heterogeneous. In phase II clinical trials in patients with other solid tumors, including colorectal cancer, breast cancer, non-small cell lung cancer, hepatocellular carcinoma, and neuroendocrine tumors, sunitinib has shown detectable but low objective response rates (10–15). To improve on sunitinib efficacy, combination therapies with cytotoxic chemotherapy, radiation therapy, and targeted agents are currently under active clinical investigation.

It is likely that resistance to sunitinib treatment develops due to the existence of compensatory pathways in both tumor blood vessels and tumor epithelial cells. At the tumor blood vessel level, preclinical and clinical studies have shown that treatment with antiangiogenic or antivascular agents leads to the compensatory induction of proangiogenic factors including VEGF, placental growth factor, interleukin-8, and basic fibroblast growth factor (16–19). These mechanisms may be responsible for tumor blood vessel resistance to sunitinib inhibition of VEGFRs and platelet-derived growth factor receptors. At the tumor epithelial cell level, sunitinib inhibition of receptor tyrosine kinase phosphorylation decreases survival signaling through AKT and extracellular signal-regulated kinase and decreases glucose uptake (20–23). However, inhibition of tumor cell growth is not long-lasting as shown by clinical trials using fluorodeoxyglucose positron emission tomography imaging. In these studies, sunitinib treatment incompletely inhibited fluorodeoxyglucose uptake or induced rebound fluorodeoxyglucose uptake during the initial post-treatment rest period (22, 23).

Overexpression of the hypoxia-inducible transcription factors, HIF-1 α or HIF-2 α has been strongly associated with cancer progression (24–29). HIF-1 is composed of the HIF-1 α and HIF-1 β subunits, and HIF-2 is composed of the HIF-2 α and HIF-1 β subunits. Whereas HIF-1 β

Received 10/2/08; revised 1/30/09; accepted 3/6/09; published OnlineFirst 5/12/09.

Grant support: National Comprehensive Cancer Network from general research support provided by Pfizer, NIH grant K22CA111897, and The University of Michigan Comprehensive Cancer Center Pilot Project Award.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: K. Burkitt and S.Y. Chun contributed equally to this work.

Requests for reprints: Long H. Dang, University of Michigan Medical Center, 1150 West Medical Center Drive, MSRB I, 6514, Ann Arbor, MI 48109. Phone: 734-615-8318; Fax: 734-763-2535. E-mail: lhdang@umich.edu

Copyright © 2009 American Association for Cancer Research.

doi:10.1158/1535-7163.MCT-08-0944

is constitutively expressed, HIF-1 α and HIF-2 α protein stability and synthesis are regulated by intratumoral hypoxia, growth factors, and genetic alterations (30–38). Induction of HIF-1 and HIF-2 transactivate gene programs important for inducing tumor angiogenesis, cancer cell growth and survival, and energy metabolism (39–42). As such, tumor induction of HIF-1 and HIF-2 may be a mechanism of escape from the effects of sunitinib therapy.

We hypothesized that inhibition of HIF-1 and HIF-2 in cancer cells would improve response to sunitinib treatment. To test this hypothesis, we generated isogenic human colon cancer cell lines with specific genetic disruption of *HIF-1 α* , *HIF-2 α* , or both *HIF-1 α* and *HIF-2 α* (*HIF-1 α* -/-, *HIF-2 α* -/-, and *HIF-1 α* -/-*HIF-2 α* -/-). The effects of sunitinib treatment, both *in vitro* and *in vivo*, were compared in parental and knockout cell lines.

Materials and Methods

Cell Lines

All cancer cell lines were acquired from the American Type Culture Collection. HCT116, LOVO, and HCT15 are human colon cancer cell lines. Isogenic cell lines with somatic disruption of *HIF-1 α* , *HIF-2 α* and *VEGF* genes were derived from HCT116 (HCT116^{*HIF-1 α* -/-}, HCT116^{*HIF-2 α* -/-}, HCT116^{*HIF-1 α* -/-*HIF-2 α* -/-}, and HCT116^{*VEGF*-/-}), LOVO (LOVO^{*HIF-1 α* -/-}), and HCT15 (HCT15^{*HIF-1 α* -/-}) cells as described previously (43). Cells were grown in McCoy's 5A medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (Invitrogen).

Cell Proliferation and Clonogenic Survival Assay

Cells were trypsinized, counted, and plated. For cell proliferation studies, cells were harvested daily for 7 days and stained with trypan blue, and viable (nonblue) cells were counted on a hemocytometer. Student's paired *t* test was used to determine statistical significance between groups. For analysis of colony formation, cells were allowed to grow undisturbed at 37°C in 5% CO₂ for 10 days and then stained with crystal violet.

Xenograft Models

Six-week-old female athymic *nu/nu* mice (Harlan) were implanted with 20 × 10⁶ cells by s.c. injection into the flanks as described previously (43). Tumor sizes in two dimensions were measured with calipers, and volumes were calculated with the formula: (*L* × *W*²) × 0.5, where *L* is length and *W* is width. Student's paired *t* test was used to determine statistical significance between groups. Mice were housed in barrier environments, with food and water provided *ad libitum* as approved by the University of Michigan Animal Care and Use Committee. Xenografts were harvested for subsequent analyses when they reached ~0.5 cm³.

Sunitinib Treatment

For sunitinib treatment, implanted tumors were allowed to grow for 2 to 4 days, and the mice were treated daily by oral gavage with sunitinib malate (Pfizer) at 40 mg/kg/d for 21 days.

Tumor Angiogenesis

Harvested xenografts were fixed in Tissue-Tek OTC compound (Sakura Finetek) and stored at -80°C. Frozen sec-

tions, 10 μ m in thickness, were prepared with a Leica Microsystems cryostat. For tumor angiogenesis, microvessel density was determined by staining sections with a monoclonal antibody against the endothelial cell-specific marker CD31 (BD Pharmingen) followed by a biotinylated secondary antibody (Jackson ImmunoResearch Laboratories) and rhodamine-streptavidin (Vector Labs). At least three sections from each of three tumors were examined under fluorescence microscopy. Results are illustrated and quantified in Fig. 3 using Image-Pro Plus software (Media Cybernetics).

Tumor Microvessel Perfusion

Mice bearing tumors were injected i.v. with Hoechst 33342 (40 mg/kg) 2 min before sacrifice. Tumors were fixed in Tissue-Tek OTC compound and stored at -80°C. Frozen sections, 10 μ m in thickness, were prepared with a Leica Microsystems cryostat and examined under fluorescence microscopy. At least three sections from each of three tumors were examined under fluorescence microscopy. Results are illustrated and quantified in Fig. 3 using Image-Pro Plus software (Media Cybernetics).

Gene Expression Profiling

HCT116 and HCT116^{*HIF-1 α* -/-*HIF-2 α* -/-} xenografts were harvested at ~0.4 cm³ and total RNA was extracted. Gene expression analyses on the samples were done at the University of Michigan Comprehensive Cancer Center Affymetrix Core Facility. Commercial high-density oligonucleotide arrays were used (GeneChip Human Genome U133A; Affymetrix) following protocols and methods developed by the supplier.

Real-time Reverse Transcription-PCR Analyses

Total RNA from xenografts were extracted, treated with DNase I, and reverse-transcribed. Real-time PCRs were done in triplicate on reverse transcription-derived cDNA, and relative values were calculated. Student's paired *t* test was used to determine statistical significance between groups.

Western Blot Analyses

Whole-cell protein extracts were prepared from cell lines, separated by electrophoresis, transferred to nitrocellulose membranes, and probed with antibodies. Antibodies were obtained from Cell Signaling Technologies (peroxidase-conjugated anti-rabbit antibody and peroxidase-conjugated anti-mouse antibody), BD Transduction Laboratories (anti-human HIF-1 α), Novus Biologicals (anti-human HIF-2 α), and Sigma (anti- α -tubulin). Antibody dilutions were as recommended by the manufacturer.

Results

Effects of Disruption of *HIF-1 α* or *HIF-2 α* on Xenograft Response to Sunitinib Treatment

To determine the effects of specifically inhibiting HIF-1 on tumor response to sunitinib, we generated a series of human colon cancer cell lines that do not express HIF-1 α : HCT116^{*HIF-1 α* -/-}, HCT15^{*HIF-1 α* -/-}, and LOVO^{*HIF-1 α* -/-}. Exons 3 and 4 of the *HIF-1 α* gene were targeted for disruption by homologous recombination as described previously


1150 *HIF-1 and HIF-2 Inhibition and Tumor Response to Sunitinib*

Figure 1. Confirmation of disruption of *HIF-1α* and/or *HIF-2α* by homologous recombination. Parental and disrupted cells were subjected to hypoxia for 24 h and harvested. Western blots using antibodies to HIF-1α and HIF-2α were done, with antibody to α-tubulin as a loading control. *c*, clone.

(43, 44). Complete loss of HIF-1α protein was confirmed by Western blot analysis (Fig. 1). To determine the effects of inhibiting HIF-2 on tumor response to sunitinib, we disrupted the *HIF-2α* gene in HCT116 to generate HCT116^{HIF-2α/-}

cells. Exons 5 and 6 of the *HIF-2α* gene loci were targeted for disruption by homologous recombination as described previously (43, 44). Complete loss of HIF-2α protein was confirmed by Western blot analysis (Fig. 1). The residual lower




Figure 2. Response to sunitinib treatment in parental, *HIF-1α*^{-/-}, and *HIF-2α*^{-/-} xenografts. Effect of sunitinib in (A) HCT116 compared with HCT116^{HIF-1α/-} xenografts, (B) HCT15 compared with HCT15^{HIF-1α/-} xenografts, (C) LOVO compared with LOVO^{HIF-1α/-} xenografts, and (D) HCT116 compared with HCT116^{HIF-2α/-} xenografts. Cells were implanted into the flanks of athymic nude mice and xenograft size was measured and calculated weekly. For sunitinib treatment, tumors were allowed to grow for 2 to 4 d, and mice were treated daily by oral gavage with sunitinib 40 mg/kg/d for 21 d. Control animals were treated with PBS (*n* = 10). *, *P* < 0.05 by Student's *t* test comparing parental with treatment or knockout xenografts. Multiple knockout clones were tested and showed similar results; for clarity, only one representative clone is presented. Supplementary Fig. S1⁵ provides results with two clones.

bands in the HCT116^{HIF-2 α -/-} and HCT116^{HIF-1 α -/-HIF-2 α -/-} cell lysates likely represent nonspecific cross-reactivity of the HIF-2 α polyclonal antisera to HIF-1 β . Specific loss of HIF-2 α function is confirmed by the down-regulation of expression of known HIF-2-regulated genes.⁴ Parental and knockout clones were implanted into the flanks of athymic nude mice. After 3 to 5 days, mice were treated with sunitinib by oral gavage, and ensuing xenograft growth was measured.

Disruption of *HIF-1 α* led to growth delays in the three human colon cancer xenografts tested. HCT116^{HIF-1 α -/-} xenografts had a ~4.5-day growth delay compared with HCT116 xenografts, HCT15^{HIF-1 α -/-} xenografts had a ~10-day growth delay compared with HCT15 xenografts, and LOVO^{HIF-1 α -/-} xenografts had a ~5-day growth delay compared with LOVO xenografts (Fig. 2A-C; Table 1). Disruption of *HIF-2 α* led to ~1.5-day growth delay in HCT116^{HIF-2 α -/-} xenografts compared with HCT116 xenografts (Fig. 2D; Table 1).

Sunitinib treatment alone led to growth delays in the three parental xenografts, with additional delay in their respective *HIF-1 α* -/- or *HIF-2 α* -/- xenografts. Sunitinib therapy delayed growth in HCT116 xenografts by ~4 days (Fig. 2A; Table 1). In *HIF-1 α* or *HIF-2 α* disrupted xenografts, sunitinib delayed growth to ~7.5 and ~18 days, respectively (Fig. 2A and D; Table 1). This additive inhibition was also observed in the HCT15 and LOVO series of cells (Fig. 2B and C; Table 1).

We speculated that the additive inhibitory effect on xenografts growth was due to improved inhibition of tumor angiogenesis and/or tumor epithelial cells growth. To evaluate tumor blood vessels, tumor angiogenesis and microvessel perfusion were assessed. In HCT116 xenografts, sunitinib treatment significantly decreased both tumor angiogenesis and microvessel perfusion, respectively (Fig. 3). When compared with sunitinib treatment alone, the combination of sunitinib treatment and disruption of *HIF-1 α* did not lead to further decreases in tumor angiogenesis and microvessel perfusion (Fig. 3). These findings were replicated in the HCT15 and LOVO series of cells (Fig. 3). Similarly, when sunitinib treatment was combined with disruption of *HIF-2 α* , there was only a slight tumor blood vessel response when compared with sunitinib treatment alone (Fig. 3). Thus, although the combination of sunitinib treatment plus disruption of *HIF-1 α* or *HIF-2 α* additively inhibits tumor xenograft growth, the combination does not additively inhibit tumor angiogenesis and microvessel perfusion (Figs. 2 and 3). This suggests that the underlying mechanism of additive inhibition might also involve alterations in tumor epithelial cell growth and is examined below in Fig. 4.

Effects of Disruption of Both *HIF- α s* on Xenograft Response to Sunitinib Treatment

HIF-1 α and *HIF-2 α* have been shown to share partial structural and functional similarities and bind to HIF-1 β to form the HIF-1 and HIF-2 heterodimers, respectively

(41, 42, 45–48). HIF-1 and HIF-2 bind to the same hypoxia response element promoter motif and transactivate both unique and overlapping sets of genes, important for tumor angiogenesis and tumor cell growth and survival (42, 49, 50). For these reasons, we hypothesized that combined inhibition of both HIF-1 and HIF-2 would further improve response to sunitinib.

To determine the effects of inhibiting both HIF-1 and HIF-2 on tumor response to sunitinib, we disrupted both *HIF- α s* genes in HCT116 cells to generate the HCT116^{HIF-1 α -/-HIF-2 α -/-} cells. Complete loss of both HIF-1 α and HIF-2 α proteins was confirmed by Western blot analysis (Fig. 1). Disruption of both *HIF- α s* led to >30-day xenograft growth delay (Fig. 4A; Table 1). Sunitinib treatment of HCT116^{HIF-1 α -/-HIF-2 α -/-} xenografts further delayed their growth, with sustained complete remission in 50% of mice (Fig. 4A; Table 1). We next examined the effects on tumor angiogenesis and microvessel perfusion. Disruption of both *HIF- α s* led to a significant decrease in both tumor angiogenesis and microvessel perfusion (Fig. 3). Combining sunitinib treatment with disruption of *HIF- α s* led to an almost complete inhibition of tumor angiogenesis and microvessel perfusion (Fig. 3).

Because both HIF-1 and HIF-2 are well known to induce VEGF production, we sought to determine if more efficient inhibition of VEGF was responsible for the enhanced anti-angiogenic response to sunitinib in the *HIF- α s* disrupted xenografts. Indeed, *VEGF* expression was partially decreased in HCT116^{HIF-1 α -/-} and HCT116^{HIF-2 α -/-} xenografts and further decreased in HCT116^{HIF-1 α -/-HIF-2 α -/-} xenografts when compared with HCT116 xenografts (Fig. 4C).

Table 1. Xenograft growth delay


Xenograft	Growth delay (d)
HCT116 to 0.3 cm ³	0.0
HCT116 + sunitinib	4.0
HCT116 ^{HIF-1α-/-}	4.5
HCT116 ^{HIF-1α-/-} + sunitinib	7.5
HCT116 ^{HIF-2α-/-}	1.5
HCT116 ^{HIF-2α-/-} + sunitinib	18.0
HCT116 ^{HIF-1α-/-HIF-2α-/-}	>30
HCT116 ^{HIF-1α-/-HIF-2α-/-} + sunitinib	>30*
HCT116 ^{VEGF-/-}	>30
HCT116 ^{VEGF-/-} + sunitinib	>30
HCT15 to 0.25 cm ³	0.0
HCT15 + sunitinib	1.0
HCT15 ^{HIF-1α-/-}	10.0
HCT15 ^{HIF-1α-/-} + sunitinib	19.0
LOVO to 0.2 cm ³	0.0
LOVO + sunitinib	7.0
LOVO ^{HIF-1α-/-}	5.0
LOVO ^{HIF-1α-/-} + sunitinib	18.0

NOTE: Xenograft growth delay was calculated as days for sunitinib-treated or knockout xenograft to reach designated size compared with parental xenografts. The designated sizes are listed in the table and shown graphically in Figs. 2 and 4.

*Complete remission in 50% of mice.

⁴Article in preparation.

1152 *HIF-1 and HIF-2 Inhibition and Tumor Response to Sunitinib*



To more directly test whether superior inhibition of VEGF enhanced tumor response to sunitinib, we disrupted the *VEGF* gene in HCT116 cells by homologous recombination. *VEGF* disruption delayed tumor growth by >30 days in HCT116^{VEGF^{-/-}} compared with their parental counterparts (Fig. 4B). However, addition of sunitinib did not further delay *VEGF^{-/-}* xenograft growth (Fig. 4B). Tumor vessel analyses show that *VEGF* disruption significantly decreased both tumor angiogenesis and microvessel perfusion (Fig. 3). Notably, the decrease in tumor angiogenesis and microvessel perfusion in *VEGF^{-/-}* xenografts was less pronounced than that observed in *HIF-1 α ^{-/-}HIF-2 α ^{-/-}* xenografts (Fig. 3). Sunitinib treatment of HCT116^{VEGF^{-/-}} xenografts also resulted in a lesser decrease in tumor angiogenesis and microvessel perfusion compared with sunitinib treatment of HCT116^{HIF-1 α ^{-/-}HIF-2 α ^{-/-}} xenografts (Fig. 3). These data suggest that the enhanced antiangiogenic effects from combining *HIF- α s* disruption and sunitinib treatment are not due to the inhibition of VEGF alone.

We next sought to determine whether additional angiogenic factors are regulated by HIF-1 and HIF-2. To systematically identify putative target genes, HCT116 and HCT116^{HIF-1 α ^{-/-}HIF-2 α ^{-/-}} xenografts were subjected to global gene expression analyses using an Affymetrix U133A GeneChip. Genes with at least a 4-fold change in expression were identified. As target genes are regulated by the binding of HIF-1 and/or HIF-2 to hypoxia response elements, the genes were further filtered by the existence of the hypoxia response element sequence [(A/G)CGTG] in their promoters.

Disruption of *HIF-1 α* and *HIF-2 α* led to decreased expression of the gene encoding the proangiogenic factor *angiopoietin-like protein 4 (ANGPTL4)* and increased expression of the gene encoding the antiangiogenic factor thrombospondin 1 (*TSP1*). To validate these microarray results, *ANGPTL4* and *TSP1* mRNA expression was measured in tumor xenografts by real-time reverse transcription-PCR. Compared with parental HCT116 xenografts, *ANGPTL4* expression was decreased by ~8-fold in HCT116^{HIF-1 α ^{-/-}HIF-2 α ^{-/-}} xenografts (Fig. 4C). Conversely, compared with parental HCT116 xenografts, *TSP1* expression was increased by ~8-fold in HCT116^{HIF-1 α ^{-/-}HIF-2 α ^{-/-}} xenografts (Fig. 4C). These data show that HIF-1 and HIF-2 inhibition not only down-regulate VEGF but also down-regulate another proangiogenic factor, *ANGPTL4*, and also up-regulate the antiangiogenic factor, *TSP1*. As such, antiangiogenic response is superior when sunitinib is combined with HIF-1 and HIF-2 inhibition compared with VEGF inhibition, because the combination disarms multiple angiogenic pathways.

Effects of Disruption of *HIF-1 α* , *HIF-2 α* , and both *HIF- α s* and Sunitinib Treatment on Tumor Epithelial Cells

Disruption of *HIF-1 α* or *HIF-2 α* enhanced tumor response to sunitinib but did not significantly alter tumor blood vessel response (Figs. 2 and 3). This suggested that disruption of *HIF-1 α* or *HIF-2 α* might directly affect tumor epithelial cell growth.

To determine the effects on epithelial cell growth, cell proliferation and clonogenic survival assay were done. In HCT116 cells, disruption of either *HIF-1 α* or *HIF-2 α* led to decreased cell growth, and disruption of both *HIF- α s* further decreased growth (Fig. 4D and E). These findings in *HIF-1 α ^{-/-}* cells were replicated in HCT15 and LOVO cell lines (Supplementary Fig. S2).⁵ In the presence of sunitinib at clinically achievable dose range (0.1 μ mol/L), no further inhibition of cell growth was observed (Fig. 4D and E). Sunitinib treatment also did not affect cell cycle parameters, rate of DNA synthesis, or cell death (data not shown).

These data illustrated that disruption of *HIF-1 α* and *HIF-2 α* in colon cancer cells had direct antitumor effect on cell growth, whereas sunitinib treatment did not. As such, targeting *HIF-1* and *HIF-2* would complement the antiangiogenic effects of sunitinib by directly inhibiting tumor epithelial cells.

Discussion

Altogether, our data show that the antitumor effect of sunitinib treatment on colon cancer xenografts is predominantly mediated by inhibition of tumor angiogenesis. In combination with sunitinib, disruption of both *HIF-1 α* and *HIF-2 α* additively inhibited tumorigenesis through two mechanisms. The first mechanism is by modulation of additional angiogenic pathways that complement those affected by sunitinib. The second mechanism is through the direct effects of *HIF-1 α* and *HIF-2 α* on tumor epithelial cell growth. We have shown previously that *HIF-1 α* promotes cell proliferation in the nonhypoxic compartment of tumor xenografts (43). Based on our *in vitro* data, *HIF-2 α* also promotes cell growth under nonhypoxic conditions. As the nonhypoxic compartment is where tumor cells continue to proliferate because of ongoing delivery of oxygen and nutrients, this compartment might allow for tumor escape despite antiangiogenic therapy. Therefore, targeting tumor epithelial cells

⁵ Supplementary material for this article is available at Molecular Cancer Therapeutics Online (<http://mct.aacrjournals.org/>).

Figure 3. Tumor vessel response to sunitinib treatment in parental, *HIF-1 α ^{-/-}*, *HIF-2 α ^{-/-}*, and *HIF-1 α ^{-/-}HIF-2 α ^{-/-}* xenografts. **A**, tumor angiogenesis (TA). **B**, tumor microvessel perfusion (MP). Parental and knockout xenografts were treated with placebo or sunitinib 40 mg/kg/d for 21 d, harvested, and fixed. For tumor angiogenesis, microvessel density was determined by staining sections with a monoclonal antibody against the endothelial cell-specific marker CD31. For tumor microvessel perfusion studies, mice were injected i.v. with Hoechst 33342 at 2 min before sacrifice. Tumors were fixed, sectioned, and examined under fluorescence microscopy. Representative photomicrographs were obtained. Original magnification, $\times 40$. Quantification of **(C)** tumor angiogenesis and **(D)** tumor microvessel perfusion. Images from three representative sections from three different tumors were quantified using Image-Pro Plus software ($n = 9$). Tumor angiogenesis and microvessel perfusion are depicted as relative to wild-type untreated xenografts.




Figure 4. Response to sunitinib treatment in parental, *HIF-1 α -/-HIF-2 α -/-*, and *VEGF-/-* xenografts. Effect of sunitinib in (A) HCT116 compared with HCT116^{*HIF-1 α -/-HIF-2 α -/-*} xenografts and (B) HCT116 compared with HCT116^{*VEGF-/-*} xenografts. Cells were implanted into the flanks of athymic nude mice and xenograft size was measured and calculated weekly. For sunitinib treatment, tumors were allowed to grow for 2 to 4 d, and mice were treated daily by oral gavage with sunitinib 40 mg/kg/d for 21 d. Control animals were treated with PBS ($n = 10$). *, $P < 0.05$ by Student's t test comparing parental with treatment or knockout xenografts. C, induction of angiogenic factors in xenografts. RNA was harvested from xenografts and subjected to real-time reverse transcription-PCR with primers for *VEGF*, *ANGPTL4*, *TSP1*, and β -*actin*. Gene expressions relative to β -*actin* are graphed ($n = 9$). *, $P < 0.05$ by Student's t test comparing treatment or knockout with parental xenografts. Multiple knockout clones were tested and showed similar results; for clarity, only one representative clone is presented. D, colony formation in response to sunitinib treatment in parental, *HIF-1 α -/-*, *HIF-2 α -/-*, and *HIF-1 α -/-HIF-2 α -/-* cell lines. Cancer cells were plated in the presence or absence of sunitinib and allowed to grow undisturbed for 10 d. Colony formation was determined by staining with crystal violet. Representative photomicrographs were obtained. Multiple knockout clones were tested and showed similar results; for clarity, only one representative clone is presented. E, cell proliferation in response to sunitinib treatment in parental, *HIF-1 α -/-*, *HIF-2 α -/-*, and *HIF-1 α -/-HIF-2 α -/-* cell lines. Cancer cells were plated in the presence or absence of sunitinib, incubated under normoxic conditions, and then counted daily for 7 d after trypan blue exclusion. Data are shown for counts at day 7 ($n = 3$). *, $P < 0.01$ by Student's t test comparing parental with *HIF-1 α -/-*, *HIF-2 α -/-*, and *HIF-1 α -/-HIF-2 α -/-* cells.

directly through inhibition of HIF-1 α and/or HIF-2 α would complement the antiangiogenic effects of sunitinib.

Our preclinical findings suggest an approach in which sunitinib may be combined with inhibitors of HIF-1 and/or HIF-2 for cancer treatment. Combining sunitinib with HIF-1 and/or HIF-2 inhibition led to additive inhibitory effects in xenografts derived from multiple cell lines. These preclinical findings suggest that this combination in patients would also lead to additive clinical benefit, with improved clinical endpoints including progression-free survival, time to progression, and likely overall survival.

To date, high-throughput small-compound screens and mechanistic studies have identified several classes of anticancer agents that disrupt HIF-1 function, including inhibition of its transcriptional activity and HIF-1 α protein

synthesis or stability (39, 51–56). Additional screening is ongoing to identify inhibitors of HIF-1 α and HIF-1 β interactions (57). Based on partial structural and functional similarities between HIF-1 and HIF-2, it is possible that many of the already identified HIF-1 inhibitors would inhibit HIF-2. Our data suggest that it may be advantageous to systematically identify compounds that are effective at inhibiting both HIF-1 and HIF-2 for cancer treatment.

The improved antiangiogenic effect of *HIF- α s* disruption plus sunitinib treatment is not mediated by an enhanced inhibition of the VEGF/VEGFR axis but likely by the inhibition of another proangiogenic factor, ANGPTL4, and induction of the antiangiogenic factor, TSP1. Our data are consistent with previous preclinical studies showing compensatory induction of other proangiogenic factors in

addition to VEGF on initiation of antiangiogenic therapy (17, 18). These data also suggest that combining sunitinib and agents primarily targeting the VEGF pathway might not improve clinical response or benefit. A potential advantage of combining sunitinib with agents targeting HIF-1 and HIF-2 is their effects on complementary angiogenic factors.

In conclusion, our study shows that effective antitumor treatment may be achieved by maximal inhibition of both tumor blood vessel and tumor epithelial cell compartments. However, important questions remain, and further investigations are ongoing in our laboratory. First, the mechanism by which HIF-1 and HIF-2 coordinate and induce tumor angiogenesis through the regulation of proangiogenic factor(s) and antiangiogenic factor(s) remains to be determined. Second, it is not entirely known how HIF-1 and HIF-2 interact and regulate cancer cell growth and survival. It is likely that the mechanisms by which HIF-1 and HIF-2 regulate cell growth and survival are unique and overlapping, and target genes controlling nutrients metabolism, growth, and survival pathways need to be identified. Further mechanistic studies in these areas will likely yield additional targets for drug development and novel combinations for cancer treatment.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Drs. Jacques Nor, Lawrence Gardner, William Ensminger, Mark Zalupski, and Douglas Blayney for critical review of the article; Joe Washburn, James McDonald, and Kerry Innes (University of Michigan Comprehensive Cancer Center Microarray Core Facility) for assistance with microarray analyses; and Linda Hartwig and Pamela Varga for administrative assistance.

References

- Mendel DB, Laird AD, Xin X, et al. *In vivo* antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. *Clin Cancer Res* 2003;9:327–37.
- O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity *in vitro* and *in vivo*. *Blood* 2003;101:3597–605.
- Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer. *Mol Cancer Ther* 2003;2:471–8.
- Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. *Mol Cancer Ther* 2003;2:1011–21.
- Potapova O, Laird AD, Nannini MA, et al. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. *Mol Cancer Ther* 2006;5:1280–9.
- Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. *J Clin Oncol* 2007;25:884–96.
- Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. *Nat Rev Drug Discov* 2007;6:734–45.
- Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. *Lancet* 2006;368:1329–38.
- Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. *N Engl J Med* 2007;356:115–24.
- Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. *J Clin Oncol* 2006;24:25–35.
- Bello CL, DePrimo SE, Friece C, et al. Analysis of circulating biomarkers of sunitinib malate in patients with unresectable neuroendocrine tumors (NET): VEGF, IL-8, and soluble VEGF receptors 2 and 3. *J Clin Oncol* 2006 ASCO Annu Meet Proc Part I 2006;24:abstract 4045.
- Saltz LB, Rosen LS, Marshall JL, et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. *J Clin Oncol* 2007;25:4793–9.
- Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. *J Clin Oncol* 2008;26:650–6.
- Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. *J Clin Oncol* 2008;26:1810–6.
- Zhu AX, Sahani DV, di Tomaso E, et al. A phase II study of sunitinib in patients with advanced hepatocellular carcinoma. *J Clin Oncol* 2007 ASCO Annu Meet Proc 2007;25:abstract 4637.
- Folkman J. A novel anti-vascular therapy for cancer. *Cancer Biol Ther* 2004;3:338–9.
- Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. *Cancer Cell* 2005;8:299–309.
- Mizukami Y, Jo WS, Duerr EM, et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1 α -deficient colon cancer cells. *Nat Med* 2005;11:992–7.
- Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. *Nat Clin Pract Oncol* 2006;3:24–40.
- Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. *Blood* 2005;105:986–93.
- O'Farrell AM, Foran JM, Fiedler W, et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. *Clin Cancer Res* 2003;9:5465–76.
- Toner JC, Mitchell PL, De Boer R, et al. PET imaging study of SU11248 in patients with advanced malignancies. *Proc Am Soc Clin Oncol* 2003;22:abstract 767.
- Banzo I, Quirce R, Martinez-Rodriguez I, et al. F-18 FDG PET/CT assessment of gastrointestinal stromal tumor response to sunitinib malate therapy. *Clin Nucl Med* 2008;33:211–2.
- Bos R, Zhong H, Hanrahan CF, et al. Levels of hypoxia-inducible factor-1 α during breast carcinogenesis. *J Natl Cancer Inst* 2001;93:309–14.
- Schindl M, Schoppmann SF, Samonigg H, et al. Overexpression of hypoxia-inducible factor 1 α is associated with an unfavorable prognosis in lymph node-positive breast cancer. *Clin Cancer Res* 2002;8:1831–7.
- Kurokawa T, Miyamoto M, Kato K, et al. Overexpression of hypoxia-inducible-factor 1 α (HIF-1 α) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. *Br J Cancer* 2003;89:1042–7.
- Birner P, Schindl M, Obermair A, et al. Overexpression of hypoxia-inducible factor 1 α is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. *Cancer Res* 2000;60:4693–6.
- Birner P, Gatterbauer B, Oberhuber G, et al. Expression of hypoxia-inducible factor-1 α in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. *Cancer* 2001;92:165–71.
- Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Relation of hypoxia inducible factor 1 α and 2 α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. *Br J Cancer* 2001;85:881–90.
- Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. *Proc Natl Acad Sci U S A* 1993;90:4304–8.
- Blancher C, Moore JW, Robertson N, Harris AL. Effects of ras and von

- Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1 α , HIF-2 α , and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. *Cancer Res* 2001;61:7349–55.
32. Richard DE, Berra E, Gothie E, Roux D, Pouyssegur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1 α (HIF-1 α) and enhance the transcriptional activity of HIF-1. *J Biol Chem* 1999;274:32631–7.
33. Karni R, Dor Y, Keshet E, Meyuhos O, Levitzki A. Activated pp60c-Src leads to elevated hypoxia-inducible factor (HIF)-1 α expression under normoxia. *J Biol Chem* 2002;277:42919–25.
34. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1 α (HIF-1 α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. *Mol Cell Biol* 2001;21:3995–4004.
35. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1 α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. *Cancer Res* 2000;60:1541–5.
36. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 α . *Genes Dev* 2000;14:34–44.
37. Zundel W, Schindler C, Haas-Kogan D, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. *Genes Dev* 2000;14:391–6.
38. Pore N, Jiang Z, Shu HK, et al. Akt1 activation can augment hypoxia-inducible factor-1 α expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. *Mol Cancer Res* 2006;4:471–9.
39. Semenza GL. Targeting HIF-1 for cancer therapy. *Nat Rev Cancer* 2003;3:721–32.
40. Goonewardene TI, Sowter HM, Harris AL. Hypoxia-induced pathways in breast cancer. *Microsc Res Tech* 2002;59:41–8.
41. Lofstedt T, Fredlund E, Holmquist-Mengelbier L, et al. Hypoxia inducible factor-2 α in cancer. *Cell Cycle* 2007;6:919–26.
42. Gordan JD, Simon MC. Hypoxia-inducible factors: central regulators of the tumor phenotype. *Curr Opin Genet Dev* 2007;17:71–7.
43. Dang DT, Chen F, Gardner LB, et al. Hypoxia-inducible factor-1 α promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts. *Cancer Res* 2006;66:1684–936.
44. Kohli M, Rago C, Lengauer C, Kinzler KW, Vogelstein B. Facile methods for generating human somatic cell gene knockouts using recombinant adeno-associated viruses. *Nucleic Acids Res* 2004;32:3–10.
45. Ema M, Taya S, Yokotani N, et al. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1 α regulates the VEGF expression and is potentially involved in lung and vascular development. *Proc Natl Acad Sci U S A* 1997;94:4273–8.
46. Flamme I, Frohlich T, von Reutern M, et al. HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 α and developmentally expressed in blood vessels. *Mech Dev* 1997;63:51–60.
47. Hogenesch JB, Chan WK, Jackiw VH, et al. Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway. *J Biol Chem* 1997;272:8581–93.
48. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. *Genes Dev* 1997;11:72–82.
49. Sowter HM, Raval RR, Moore JW, Ratcliffe PJ, Harris AL. Predominant role of hypoxia-inducible transcription factor (HIF)-1 α versus HIF-2 α in regulation of the transcriptional response to hypoxia. *Cancer Res* 2003;63:6130–4.
50. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1 α (HIF-1 α) and HIF-2 α in hypoxic gene regulation. *Mol Cell Biol* 2003;23:9361–74.
51. Escuin D, Simons JW, Giannakakou P. Exploitation of the HIF axis for cancer therapy. *Cancer Biol Ther* 2004;3:608–11.
52. Kung AL, Zabludoff SD, France DS, et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. *Cancer Cell* 2004;6:33–43.
53. Rapisarda A, Uranchimeg B, Sordet O, et al. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. *Cancer Res* 2004;64:1475–82.
54. Tan C, de Noronha RG, Roecker AJ, et al. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. *Cancer Res* 2005;65:605–12.
55. Chau NM, Rogers P, Aherne W, et al. Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1 α induction in response to hypoxic stress and growth factors. *Cancer Res* 2005;65:4918–28.
56. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. *Nat Rev Drug Discov* 2003;2:803–11.
57. Scheuermann TH, Yang J, Zhang L, Gardner KH, Bruck RK. Hypoxia-inducible factors Per/ARNT/Sim domains: structure and function. *Methods Enzymol* 2007;435:3–24.

Molecular Cancer Therapeutics

Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment

Kyunghee Burkitt, Sang Y. Chun, Duyen T. Dang, et al.

Mol Cancer Ther 2009;8:1148-1156. Published OnlineFirst May 12, 2009.

Updated version Access the most recent version of this article at:
doi:[10.1158/1535-7163.MCT-08-0944](https://doi.org/10.1158/1535-7163.MCT-08-0944)

Supplementary Material Access the most recent supplemental material at:
<http://mct.aacrjournals.org/content/suppl/2009/05/05/1535-7163.MCT-08-0944.DC1>

Cited articles This article cites 57 articles, 32 of which you can access for free at:
<http://mct.aacrjournals.org/content/8/5/1148.full#ref-list-1>

Citing articles This article has been cited by 5 HighWire-hosted articles. Access the articles at:
<http://mct.aacrjournals.org/content/8/5/1148.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://mct.aacrjournals.org/content/8/5/1148>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.